(GILD) Gilead Sciences, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(GILD) Gilead Sciences, Inc. Bundle
Actionable Strategy Starts Here
This Gilead Sciences, Inc. BCG Matrix is a company-specific strategy tool used to assess its products or business units as Stars, Cash Cows, Question Marks, or Dogs. The page already shows a real preview of the actual analysis, so you can see the format and content before you buy. Purchase the full version to get the complete ready-to-use report.
Stars
Biktarvy, $13.4B 2024 sales
Biktarvy generated $13.4B in 2024 sales, making it Gilead Sciences, Inc.'s biggest product and top HIV brand. In BCG terms, it is a Star: the core growth engine in a still-expanding HIV treatment market. Strong volume, premium pricing, and broad use in first-line therapy keep cash generation and share high.
Descovy PrEP, about $2.4B 2024 sales
Descovy PrEP is a Star for Gilead Sciences, Inc., with about $2.4 billion in 2024 sales and strong U.S. demand. The HIV PrEP market is still growing as screening and uptake improve, and Gilead keeps the dominant branded position in this niche. That scale and category leadership support high growth, even as competition stays limited.
Yescarta, about $1.7B 2024 sales
Yescarta is a Star in Gilead Sciences, Inc.’s BCG Matrix: it delivered about $1.7B in 2024 sales and remains the leading CAR-T therapy in large B-cell lymphoma. Its growth is helped by use earlier in treatment and wider adoption across hematology centers. This makes Yescarta one of Gilead Sciences, Inc.’s fastest-growing oncology assets.
Trodelvy, about $1.3B 2024 sales
Trodelvy fits a Star profile in Gilead Sciences, Inc. BCG Matrix: 2024 sales were about $1.3B, and its use is expanding in metastatic breast and bladder cancers. Oncology is growing faster than Gilead Sciences, Inc.'s legacy antivirals, so Trodelvy is still building share across new tumor settings. That mix supports high growth, with room to scale if uptake stays strong.
- 2024 sales: about $1.3B
- ADC in breast and bladder cancers
- Faster growth than antivirals
- Share still expanding
Tecartus, about $0.4B 2024 sales
Tecartus was a "Question Mark" in Gilead Sciences, Inc. BCG terms: 2024 sales were about $0.4B, far below Yescarta, but it matters as a CAR-T asset in mantle cell lymphoma and B-ALL. The market is smaller, yet label expansion can still lift revenue from a low base.
2024 sales: about $0.4B
Targets mantle cell lymphoma and B-ALL
Smaller market than Yescarta
New indications could drive growth
Gilead’s Star Drugs Keep Growth Powering Forward
Biktarvy, Descovy PrEP, Yescarta, and Trodelvy are Gilead Sciences, Inc.'s Stars: each has strong sales, leading share, and growth in HIV or oncology. In 2024, Biktarvy led at $13.4B, while Descovy PrEP, Yescarta, and Trodelvy added about $2.4B, $1.7B, and $1.3B. These assets still drive growth.
| Asset | 2024 Sales | BCG Role |
|---|---|---|
| Biktarvy | $13.4B | Star |
| Descovy PrEP | $2.4B | Star |
| Yescarta | $1.7B | Star |
| Trodelvy | $1.3B | Star |
What is included in the product
Detailed Word Document
Gilead’s BCG Matrix maps HIV and Hep C cash cows, oncology stars, and pipeline question marks.
Editable Excel File
Quick BCG view of Gilead Sciences to spot cash cows, stars, and drag areas fast.
Reference Sources
Provides credible source backing for Gilead Sciences, Inc., making key assumptions easy to verify and decisions faster to defend.
Cash Cows
Epclusa, about $2.7B 2024 sales
Epclusa is Gilead Sciences, Inc.'s core hepatitis C cash cow, with about $2.7B in 2024 sales. It sits in a mature, low-growth market, but Gilead still holds major share.
The brand keeps producing strong cash with limited promotion, so margins stay attractive. That makes Epclusa a classic BCG Cash Cow for funding newer pipeline bets.
Harvoni, about $1B 2024 sales
Harvoni remains a cash cow for Gilead Sciences, Inc., with about $1.0 billion in 2024 sales. Growth is limited because hepatitis C is now a mature, highly treated cure market, so new patient demand is thin. Even with generic pressure, Harvoni still throws off strong cash flow thanks to its legacy scale and low ongoing investment needs.
Vemlidy, about $1B 2024 sales
Vemlidy is a mature chronic HBV therapy with steady refill demand, and Gilead Sciences, Inc. reported about $1B in 2024 sales for the brand. Its long-term use in a defined specialty base keeps churn low and commercial volatility limited. That makes it a Cash Cow that helps support Gilead Sciences, Inc.'s margin and cash flow.
Letairis, mature PAH franchise
Letairis is a mature pulmonary arterial hypertension brand in a niche, chronic-use market, so it needs little extra growth spend and keeps serving a small, sticky patient base. PAH affects only about 15 to 50 people per 1 million adults worldwide, which fits a high-share, low-growth cash-cow profile.
- Chronic therapy supports steady refills
- Niche prevalence limits growth needs
- Low promo spend fits cash-cow logic
- Established brand supports durable cash flow
Its value comes less from expansion and more from repeat use in a long-term disease setting.
AmBisome, mature anti-fungal brand
AmBisome is a mature, specialty anti-infective for serious invasive fungal infections, where mortality can exceed 30% in high-risk patients. Demand stays steady because it is medically necessary, not optional, and growth is limited. That makes it a classic Cash Cow for Gilead Sciences, Inc., with recurring cash and little need for big new spending.
- Stable hospital-driven demand
- High clinical need, low growth
- Cash flow with limited expansion
Gilead’s Cash Cows Keep Funding Growth
Gilead Sciences, Inc.'s Cash Cows are mature brands that still generate strong, low-cost cash. Epclusa, Harvoni, and Vemlidy each had about $1.0B to $2.7B in 2024 sales, while Letairis and AmBisome rely on steady chronic or hospital demand. They fund newer growth bets with limited reinvestment.
| Brand | 2024 Sales | Cash Cow Signal |
|---|---|---|
| Epclusa | $2.7B | High share, mature HCV |
| Harvoni | $1.0B | Legacy demand, low spend |
Preview the Actual Deliverable
Gilead Sciences, Inc. Reference Sources
This Gilead Sciences, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo content or missing sections—just the full, polished report ready for immediate use. Once purchased, you’ll get the same file for downloading, sharing, or presenting with confidence.
Dogs
Truvada, generic HIV erosion
Truvada is now a Dogs asset for Gilead Sciences, Inc.: generic entry in the U.S. since 2020 and internal HIV cannibalization crushed growth. Gilead Sciences, Inc. no longer breaks out Truvada sales, which signals how small it has become versus newer HIV drugs. By 2025, it is mainly a low-growth legacy cash source.
Atripla, generic legacy HIV therapy
Atripla, Gilead Sciences, Inc.’s 2006 single-tablet HIV regimen, is now a classic Dog in the BCG Matrix. Generic competition and newer regimens have driven it into decline, and Gilead’s 2025 HIV revenue was led by Biktarvy and Descovy, while Atripla was not a material disclosed sales line.
Stribild, genericized HIV brand
Stribild is an older four-drug HIV single-tablet regimen that has been overtaken by newer, safer, simpler options like Biktarvy. Its commercial case is weak in 2025 because Gilead's HIV growth is now driven by newer brands, while Stribild is genericized and contributes little strategic value. In BCG terms, it fits the Dog bucket: low growth, low share, and limited reinvestment case.
Complera/Eviplera, mature HIV combo
Complera/Eviplera is a mature HIV regimen in Gilead Sciences, Inc.’s Dogs bucket: demand keeps shrinking as newer integrase-based therapies like Biktarvy take share. It is no longer a growth driver, and its role is mainly legacy maintenance, not portfolio expansion.
- Legacy HIV combo, weak demand.
- Newer integrase regimens gained share.
- Not fit for growth portfolio.
Ranexa, chronic angina franchise in decline
Ranexa is a classic Dog in Gilead Sciences, Inc.'s BCG mix: an older chronic angina drug with low growth and little strategic value. After patent loss and generic entry, its market power fell sharply, and it no longer acts as a meaningful earnings driver. In Gilead Sciences, Inc.'s 2025 reporting, Ranexa is not highlighted as a material product, which fits a low-share, decline-stage asset.
- Older cardiovascular brand
- Generic pressure erased pricing power
- Low growth, low share, low priority
Gilead’s Aging HIV Brands: The Dogs Facing Generic Pressure
In 2025, Gilead Sciences, Inc.’s Dogs are older HIV and legacy brands with generic pressure, shrinking demand, and no material disclosed sales. Truvada, Atripla, Stribild, Complera/Eviplera, and Ranexa sit in the low-growth, low-share bucket while Biktarvy and Descovy drive the HIV franchise.
| Product | Dog signal |
|---|---|
| Truvada | Generic since 2020 |
| Atripla | No material 2025 sales line |
Question Marks
Yeztugo, FDA approved Jun 2025
Yeztugo (lenacapavir), FDA approved in June 2025, is a Question Mark in Gilead Sciences, Inc.’s BCG matrix: it opens a large HIV PrEP market with strong growth, but share is still early-stage. Gilead priced Yeztugo at about $28,000 a year, so uptake will hinge on access and payer wins. Gilead must spend heavily on education and rollout to turn demand into sales.
Sunlenca, niche HIV capsid inhibitor
Sunlenca (lenacapavir) is a first-in-class HIV capsid inhibitor for heavily treatment-experienced adults, with twice-yearly dosing after the start-up phase. It is innovative, but its use is narrow: this niche sits far below Gilead Sciences, Inc.’s >$18 billion HIV franchise. That makes it a Question Mark in BCG terms, with platform value but still limited current share.
Livdelzi, approved 2024
Livdelzi (seladelpar) was approved by the US FDA in June 2024 for primary biliary cholangitis, a rare liver disease affecting about 100,000 people in the US. The market is still early, but it has room to grow because only part of the eligible pool is treated. For Gilead Sciences, Inc., this makes Livdelzi a Question Mark: growth potential is real, but share depends on fast commercial execution and physician uptake.
GS-1720, investigational HIV long-acting program
GS-1720 is a classic Question Mark in Gilead Sciences, Inc.'s BCG mix: high upside, zero commercial share at the end of 2025 because it is still investigational. If Gilead Sciences, Inc. proves long-acting HIV dosing, this late-stage asset could strengthen a market where Gilead Sciences, Inc. already generated $19.6 billion in total revenue in 2024, with HIV as the core driver.
- No 2025 sales yet
- High-risk, high-reward bet
- Could reshape HIV care
- Needs trial success first
GS-4182, investigational HIV long-acting program
GS-4182 is a Question Mark in Gilead Sciences, Inc. BCG view: it targets the expanding HIV prevention and treatment market, but it is still pre-commercial and has no revenue base. Gilead Sciences, Inc. reported 2025 product revenue of about $28.8 billion, so GS-4182 could matter if it converts clinical progress into sales. If approved, it could add a new long-acting growth leg.
- Pre-commercial, zero revenue today
- Fits a growing HIV market
- Potential future growth driver
- High upside, execution risk
Gilead’s Question Marks: Big Upside, But Commercial Proof Still Needed
Gilead Sciences, Inc.’s Question Marks are mostly early-stage HIV and specialty assets with high upside but little current share. Yeztugo and Sunlenca target the HIV market, while Livdelzi is still scaling in rare liver disease; GS-1720 and GS-4182 remain pre-commercial. The theme is clear: strong science, but revenue depends on payer access, launch speed, and trial wins.
| Asset | 2025 status | BCG view |
|---|---|---|
| Yeztugo | FDA approved | Question Mark |
| Sunlenca | Niche use | Question Mark |
| Livdelzi | Early launch | Question Mark |
| GS-1720 | Investigational | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.